HK:2137 Stock Latest News
Company AnnouncementsBrii Biosciences Launches BRiSC siRNA Platform to Drive Next-Generation RNA Therapies2w ago
Company AnnouncementsBrii Biosciences Issues New Share Options and RSUs Under 2023 Incentive Schemes3w ago
Company AnnouncementsBrii Biosciences Narrows Interim Loss as HBV and RNA Pipelines Advance2M ago- Company AnnouncementsBrii Biosciences Sets August Board Meeting to Approve 2026 Interim Results2M ago
Company AnnouncementsBrii Biosciences Posts Promising Phase 2b Hepatitis B Data but Elebsiran Future Clouded by Arbitration4M ago
Company AnnouncementsBrii Biosciences Launches HK$60 Million Share Buy-back to Signal Confidence and Unlock Value4M ago
Company AnnouncementsBrii Biosciences Warns Hepatitis B Drug Program at Risk Amid Vir Arbitration5M ago
Company AnnouncementsBrii Biosciences Data Backs Shorter NRTI Use in Next-Generation HBV Therapies6M ago
Company AnnouncementsBrii Biosciences Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority6M ago
Company AnnouncementsBrii Biosciences Launches Arbitration Against Vir Over Hepatitis B Drug Manufacturing Rights6M ago
Company AnnouncementsBrii Biosciences Narrows 2025 Loss as Costs Fall and Revenue Emerges7M ago
Company AnnouncementsBrii Biosciences Confirms 2025 PFIC Status, Issues Tax Statement for U.S. Holders7M agoCompany AnnouncementsBrii Biosciences Sets March 2026 Board Meeting to Approve 2025 Annual Results7M ago
Company AnnouncementsBrii Biosciences Reports Promising Results from Phase 2 HBV Study11M ago
Company AnnouncementsBrii Biosciences’ Phase 2 Study Shows Promise in Hepatitis B Treatment11M ago- Company AnnouncementsBrii Biosciences Grants 600,000 Share Options to Enhance Strategic Advisory Services1y ago
- Company AnnouncementsBrii Biosciences Grants Share Options and RSUs to Align Employee Interests1y ago
Company AnnouncementsBrii Biosciences Revises Fund Allocation to Boost Therapeutic Programs1y ago